Applied Genetic Technologies Current Ratio 2013-2021 | AGTC

Applied Genetic Technologies current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Applied Genetic Technologies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.11B $0.02B 5.57
2021-03-31 $0.11B $0.02B 6.83
2020-12-31 $0.06B $0.01B 3.87
2020-09-30 $0.07B $0.01B 5.27
2020-06-30 $0.08B $0.01B 6.40
2020-03-31 $0.09B $0.01B 6.46
2019-12-31 $0.07B $0.02B 4.33
2019-09-30 $0.07B $0.01B 7.95
2019-06-30 $0.08B $0.01B 9.01
2019-03-31 $0.09B $0.01B 10.88
2018-12-31 $0.10B $0.02B 4.91
2018-09-30 $0.11B $0.03B 4.32
2018-06-30 $0.11B $0.01B 7.58
2018-03-31 $0.12B $0.02B 6.61
2017-12-31 $0.12B $0.02B 6.49
2017-09-30 $0.13B $0.02B 5.71
2017-06-30 $0.13B $0.03B 4.63
2017-03-31 $0.14B $0.03B 4.24
2016-12-31 $0.12B $0.04B 2.80
2016-09-30 $0.14B $0.05B 2.68
2016-06-30 $0.10B $0.06B 1.87
2016-03-31 $0.14B $0.05B 2.51
2015-12-31 $0.15B $0.05B 2.84
2015-09-30 $0.17B $0.06B 2.86
2015-06-30 $0.06B $0.01B 13.82
2015-03-31 $0.07B $0.00B 17.17
2014-12-31 $0.08B $0.00B 28.43
2014-09-30 $0.09B $0.00B 28.76
2014-06-30 $0.08B $0.00B 29.77
2014-03-31 $0.03B $0.00B 11.77
2013-12-31 $0.00B 0.00
2013-09-30 $0.00B 0.00
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B 0.00
2012-06-30 $0.00B $0.00B 0.73
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.111B $0.001B
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76